Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
+$0.00 today
- Market cap
- $567.69M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 0.49M
Average 0.16M
ENTX Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Entera Bio Ltd.NASDAQ: ENTX
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$3.54M, compared with -$2.56M a year earlier. Trailing-twelve-month operating income was -$12.51M.
Context
- Operating income amounted to 27450.0% of revenue in FY2025, up 22154.4 pp from a year earlier.
- Operating income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether operating income reaches the consensus estimate from 3 analysts of -$22.98M (-99.3%) for the fiscal year ending Dec 2026, a slowdown from the -20.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$3.54M-16.3% QoQ
- Last fiscal yearDec 2025
- -$11.53M-20.3% YoY
- LTMMar 2026
- -$12.51M-24.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -38.1% | — | — |
| 1 year | -20.3% | -99.3% | -79.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (11.53M) USD
- Year-over-year change
- -20.3%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (11.53M) | -20.3% |
| FY2024 | 2024-12-31 | (9.59M) | -7.2% |
| FY2023 | 2023-12-31 | (8.94M) | +31.6% |
| FY2022 | 2022-12-31 | (13.07M) | -7.0% |
| FY2021 | 2021-12-31 | (12.22M) | — |
Operating Income vs competitors
How ENTX compares with its peers on the latest reported figures
- ENTX's LTM Mar 2026 operating income of -$12.51M is the 4th highest of the 10 companies compared; the peer median is -$43.03M.
- Its year-over-year change of -24.0% is the 9th highest of 10, against a peer median of +22.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $13.51M | +118.2% | — | 24.7% | |
| LTM Mar 2026 | $8.2M | +108.1% | — | 6.6% | |
| LTM Apr 2026 | -$10.68M | +18.8% | — | — | |
| LTM Mar 2026 | -$12.51M | -24.0% | — | — | |
| LTM Mar 2026 | -$32.31M | -71.6% | — | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | -$43.03M | +33.1% | — | 359.1% |
| LTM Mar 2026 | -$74.65M | +22.0% | — | 496.4% | |
| LTM Mar 2026 | -$83.72M | +21.0% | — | — | |
| LTM Mar 2026 | -$87.64M | +23.2% | — | 7641.0% | |
| LTM Mar 2026 | -$114.61M | +9.5% | — | — | |
| Peer median (excluding ENTX) | -$43.03M | +22.0% | — | 359.1% | |
Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 571K | 134K | 0 | 181K | 42K |
| Cost of Revenue | 373K | 165K | 56K | 172K | 42K |
| Gross Profit | 198K | (31K) | (56K) | 9K | 0 |
| Gross Margin | 34.7% | -23.1% | — | 5.0% | 0.0% |
| Research & Development | 6.77M | 5.78M | 4.45M | 4.5M | 6M |
| Selling, General & Admin | 5.69M | 7.25M | 4.43M | 5.1M | 5.53M |
| Operating Expenses | 12.42M | 13.04M | 8.88M | 9.59M | 11.53M |
| Depreciation & Amortization | 53K | 64K | 56K | 46K | 30K |
| EBITDA | (12.16M) | (12.87M) | (8.8M) | (9.48M) | (11.41M) |
| EBITDA Margin | -2130.3% | -9604.5% | — | -5238.1% | -27164.3% |
| Operating Income | (12.22M) | (13.07M) | (8.94M) | (9.59M) | (11.53M) |
| Operating Margin | -2139.6% | -9752.2% | — | -5295.6% | -27450.0% |
| Interest Income | 0 | 83K | 31K | 58K | 0 |
| Interest Expense | 29K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (29K) | 134K | 80K | 58K | 90K |
| Income Before Tax | (12.25M) | (12.93M) | (8.86M) | (9.53M) | (11.44M) |
| Pre-Tax Margin | -2144.7% | -9652.2% | — | -5263.5% | -27235.7% |
| Income Tax Expense | (59K) | 137K | 29K | 14K | 0 |
| Net Income | (12.19M) | (13.07M) | (8.89M) | (9.54M) | (11.44M) |
| Net Margin | -2134.3% | -9754.5% | — | -5271.3% | -27235.7% |
| EPS (Basic) | (0.47) | (0.45) | (0.31) | (0.25) | (0.25) |
| EPS (Diluted) | (0.47) | (0.45) | (0.31) | (0.25) | (0.25) |
| Weighted Avg Shares | 26.13M | 28.81M | 29.01M | 37.65M | 46.19M |
| Weighted Avg Shares (Diluted) | 26.13M | 28.81M | 29.01M | 37.65M | 46.19M |
Entera Bio Ltd.
NASDAQ:ENTX
Intrinsic Alpha fair value
Locked
Current Price
$3.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.